Metastatix Inc., an Atlanta-based drug company focused on cancer and HIV, has raised $3.6 million in Series A funding. H.I.G. Ventures led the deal, and was joined by The Aurora Funds, CM Capital, SR One and MedImmune Ventures. Existing shareholders Georgia Venture Partners and Centrosome Ventures also participated. www.metastatix.com